Novo Nordisk and Deep Apple Therapeutics have announced a research collaboration and exclusive worldwide license agreement to discover and develop oral small molecule therapeutics.  The new drugs will be directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity.  Under the terms of the agreement, Deep Apple will discover and optimise compounds using […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!